Navigation Links
TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer
Date:9/30/2010

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.

Erlotinib has been shown to significantly increase survival for patients with previously treated advanced NSCLC. Certain groups of patients with NSCLC, such as those with a particular type of cancer - adenocarcinoma , women, Asian ethnicity and non (minimal) smokers are reported to be more likely to have tumor responses to EGFR TK inhibitors (TKIs) than other groups. However, results from the TRUST study suggest that erlotinib can benefit a wide range of patients, including those who have previously been thought unlikely to benefit from this treatment.

The large, global, open-labeled, phase IV trial TRUST study included the participation of 513 centers across 51 countries, culminating safety data from more than 6,500 patients. In patients with advanced NSCLC, the progression-free survival and overall survival in this study were 3.25 months and 7.9 months, respectively, and the disease control rate (defined as the sum complete response, partial response, or stable disease) was 69 percent.

As a post marketing surveillance trial (phase IV) occurring after erlotinib received permission to be sold, the study provided an opportunity to evaluate the efficacy and safety of this medication in a broad patient population in a real-life clinical setting. Furthermore, it included patients with advanced stage IIIB/IV NSCLC who had previously failed on or were considered unsuitable to receive standard chemotherapy or radiotherapy and were ineligible for other erlotinib trials.

"The criteria used for selecting the most appropriate therapy for a patient are of particular interest to physicians," explains lead investigator Martin Reck, MD, PhD. "Tumors with EGFR mutations have been shown to be highly responsive to EGFR TKIs. Although patients whose tumors have these mutations are likely to obtain a greater magnitude of benefit from EGFR TKIs such as erlotinib, it is important to note that the absence of these mutations does not necessarily result in a lack of benefit with erlotinib therapy."


'/>"/>

Contact: Kaitlin Doody
kdoody@spectrumscience.com
202-587-2553
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Medibank Health Solutions: The New Name to Trust in Workplace Health
2. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2009 Financial Results
3. Three NHS Trusts Choose BigHand Voice Technology Under YHCPC Framework Agreement
4. BestMassage.com Receives Award for Customer Trust
5. BioMed Realty Trust Promotes Matthew G. McDevitt to Executive Vice President, Real Estate
6. Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 260,500 Square Foot Medical Office Portfolio in Indiana
7. Healthcare Realty Trust Announces Fourth Quarter Results
8. PIA Hails Removal of Medical Malpractice Insurers From Bill Restricting Insurance Antitrust Exemption
9. Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results
10. Pelosi, Senior Democrats Remarks at News Conference on Repealing Health Insurance Industry Anti-Trust Exemption
11. Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 60,300 Square Foot Medical Office Building in Sugar Land, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
Breaking Medicine Technology: